Objectives: To observe the effect of fish oil supplementation on arterial elasticity and blood pressure (BP) in overweight hypertensive patients. Subjects and methods: This was a double-blind, randomized and placebo-controlled clinical study, in which 52 overweight hypertensive patients from a community were selected and randomly allocated to two groups (26 in the fish oil group (3 g day À1
Introduction
Epidemiologic evidences indicated that eating more fish may benefit people with high risk of ischemic heart disease (IHD), including patients with hypertension (Burr et al., 1989; De Deckere et al., 1998; GISSI-Prevenzione Investigators, 1999) .
Clinical trials have showed that n-3 fatty acids (fish oil, flaxseed oil or purified eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA)) supplementation can improve arterial elasticity in normotensive subjects with dyslipidemia, obesity or diabetes (McVeigh et al., 1994; Nestel et al., 1997 Nestel et al., , 2002 .
Decreased arterial elasticity is believing as an important predictor of cardiovascular outcome in hypertensive patients (Laurent et al., 2001a) . Elastic artery stiffening, as an age-related process, is accelerated in the presence of hypertension (Najjar et al., 2005) . Improvement of arterial stiffening could be obtained by antihypertensive treatments, which has a favorable independent effect on survival in hypertensive patients with advanced renal disease (London et al., 2004) . Results about the effects of n-3 fatty acids on blood pressure (BP) were various in the different reports (Russo et al., 1995; Prisco et al., 1998; Miyajima et al., 2001) .
The purpose of the present study is to investigate the effects of fish oil supplementation on arterial elasticity, and on BP as well, in overweight Chinese hypertensive patients.
Study design
This is a double-blind, randomized and placebo-controlled clinical study, in which 52 overweight hypertensive patients from a community in Northwest China were selected and randomly allocated to two groups: 26 cases in the fish oil group (3 g day
À1
, fish oil capsules contained EPA 540 mg, DHA 360 mg) and another 26 subjects in the placebo group (only three capsules per day), respectively. Fish oil capsules were from ALASKA premium deep-sea salmon fish oil. Each 1-g capsules contained EPA 180 mg, DHA 120 mg and tocopherol 10 IU. Each subject consumed three 1-g capsules per day. The placebo capsules were made in Pharmaceutical Preparation Section, First Hospital, Xi'an Jiaotong University.
Height, weight and arterial elasticity of each case were measured both in the baseline and in the end of follow-up time. At same time, fasting blood samples were collected for measuring serum lipids, soluble vascular cell adhesion molecule-1 (sVCAM-1), leptin, insulin, glucose and free fatty acid (FFA) composition. Seated BP in the morning was measured every 2 weeks.
Every selected case was asked to sign a written the informed consent approved by the institutional review board before the study. The study protocol was reviewed and approved by the Research Ethics Committee of Xi'an Jiaotong University. (Kanazawa et al., 2002) : body mass index X23 as overweight. Of 52 selected cases, 26 were first diagnosed hypertension, the rest of 26 cases had suffered from hypertension at different times and taking antihypertensive medicine, including captopril, metoprolol and hydrochlorothiazide and so on. Complicated subjects with target organ damage were not selected. The selected cases were not allowed to take any medicines, including antihypertensive drugs 2 weeks before the study, and were also asked to stop drinking.
Subject exclusion criteria. Subject exclusion criteria included having history of secondary hypertension, diabetes, coronary heart disease, chronic liver disease and chronic kidney disease and taking vitamin and other supplements or antilipidemic medicine or refusal to comply with certain dietary requirements (avoiding fish and plant n-3 fatty acids foods).
Follow-up. All the selected cases were followed up every 2 weeks and total follow-up period was 8 weeks. During the whole study period, the subjects maintained their normal activities. Supervision visits at least twice a week by telephone call or home spot-checks. The compliance was assessed by counting the rest of capsules and checked by measuring serum FFA composition.
During the follow-up, nine cases were dropped out, of them three from the fish oil supplement group and six from the placebo group. Of those nine cases, six took their assigned capsules less than 67% or did not wish to take the capsules were excluded in a 'run-in' phase and another three subjects in the placebo group were withdrawn from the study because their work needed often going out. At the end, total 43 subjects completed the study: 23 in the fish oil group and 20 in the placebo group.
Lab study Arterial elasticity measurement. Arterial elasticity indexes (C 1 -large artery and C 2 -small artery) were measured as described by Duprez et al. (1998) with CVProfilor DO-2020 (Hypertension Diagnostics Inc, Minneapolis, MN, USA). Radial arterial pulse waves were recorded non-invasively with an arterial tonometer sensor array. The waveform was calibrated by the oscillometric method with a cuff on the opposite arm and a calibration system internal to the Nellcor device. The tonometer sensor array adjusted itself automatically to obtain the optimal waveform and repeated its calibration until the waveform was stable. At that point, 30-s long analog tracings of the radial artery waveform were digitized at 200 samples per second and stored in a personal computer system for elasticity analysis. The pulse wave of an average beat representative of the 30 s period was constructed. Arterial elasticity indexes (C 1 and C 2 ) were derived from a third-order four-element modified Windkessel model which can reproduce arterial pressure waveforms including both exponential and oscillatory pressure decays observed during the diastolic portion of the cardiac cycle.
Blood pressure measurement Seated BP was measured in the morning after resting for 5 min, at least three measurements at 30-s interval, recorded was their average. Systolic BP was defined as the appearance of the first Korotkoff sound and diastolic BP as the disappearance of the fifth Korotkoff sound.
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Biochemics analyses
Serum was separated from chilled blood samples and frozen at À80 1C. Measurements were carried out in batches for plasma glucose, cholesterol and triglycerides using enzymatic kits with a Cobas-Bio automated analyzer (Roche Diagnostic Systems, Basel, Switzerland). Serum FFA was measured by high-performance liquid chromatogram using direct derivatization method (Miwa et al., 1987) . HDL cholesterol was separated from plasma by selective precipitation of other lipoproteins. Plasma insulin and leptin were measured by radioimmunoassay.
Statistical analysis
Differences in baseline of subject characteristics were determined by t-test, and repeated measures analysis of variance (RM-ANOVA) was used to determine effects of the intervention. The group Â time (before and after intervention) interaction was used to test the global hypothesis that the changes in the levels of the variables over the period of treatment were parallel for the two treatments. Statistical significance was established at Po0.05.
Results
1. Subject characteristics of two groups at baseline show no differences between them (Table 1) . 2. After 8 weeks follow-up, the serum n-3 polyunsaturated fatty acid (PUFA) levels increased from 65.1714.5 to 79.4723.5 mmol l
À1
(mean7s.d.), PUFA/saturated fatty acid (SFA) ratio increased from 1.07570.169 to 1.22470.208 in the fish oil group, but no changes were found in the placebo group (see Table 2 ). The changes of n-3 PUFA level and PUFA/SFA (P/S) ratio across the two groups were significant (P ¼ 0.027 and P ¼ 0.008, respectively, RM-ANOVA). 3. Artery elasticity changes (see Table 3 ) as shown in Table 3 , after 8 weeks fish oil supplementation the large artery elasticity was greatly improved in the fish oil group, C 1 increased by 21%, from 12.873.74 to 15.4974.76 ml mm Hg À1 Â 10, in contrast in the placebo, the C 1 was unchanged (13.3573.82 and 12.9773.39 ml mm Hg À1 Â 10). The changes in C 1 across the two groups were significant (P ¼ 0.027, RM-ANOVA). No changes were found in small artery elasticity and BP, either systolic or diastolic pressure, and pulse pressure as well after 8 weeks of fish oil supplementation in the fish oil group or between the two groups. 4. The changes of large arterial elasticity (DC 1 ) are significantly associated (r ¼ 0.415, P ¼ 0.011) with the changes of fasting serum P/S ratio (DP/S ratio) in all overweight hypertensive patients after 8 weeks intervention (Figure 1 ). Overweight hypertensive patients S Wang et al 5. About the plasma lipids profile, serum leptin and sVCAM-1 levels did not change over time with either treatment or placebo (data not shown).
Discussion
The major finding of this study was that in overweight hypertensive patients after 8 weeks fish oil supplementation, the large arterial elasticity was certainly improved and no effects on BP and heart rate were found, it suggested that fish oil has direct effect on elastic arteries. The result was consistent with other studies (McVeigh et al., 1994; Nestel et al., 1997 Nestel et al., , 2002 O'Keefe et al., 2006) . Large arterial stiffening was associated with hypertension, but both are not identified. Hypertension associated with large artery damage may present as structural and functional alterations. Structural alterations comprise intima-media thickening, plaque formation, stenosis of the artery and formation of aneurysms. Functional alterations comprise endothelial dysfunction and alterations of the mechanical properties of the arterial wall with increasing stiffness and loss of the Windkessel function. Loss of central artery elastic properties will ensue an early reflection of the pulse wave with a resulting increase in central systolic and central diastolic pressure. On the other hand, large arterial elasticity is BP dependent, arteries become stiffer at high pressure. However, the sustained increase in BP observed in essential hypertension is a trigger for the development of arterial wall hypertrophy, which in turns leads to a decrease in the stiffness of the wall material (Young's elastic modulus) and thus display normal stiffness (Laurent, 1995) . Therefore, it is easy to understand that fish oil supplementation improves large arterial elasticity but has no effect on BP in overweight hypertensive patients. Considering that decreased large arterial elasticity or increased arterial stiffness has predictive value for total and cardiovascular mortality, coronary morbidity and mortality in patients with hypertension (Laurent et al., 2001b; Boutouyrie et al., 2002) , the benefit of n-3 fatty acid in people at high risk for IHD may be associated with the improvement of large arterial elasticity.
The mechanisms responsible for the improvement of large arterial elasticity by fish oil deserve discussion. Arterial elasticity represents elastic properties of the proximal arterial system to changes in volume and pressure, or the distensibility. Thus, stiffness increases or elasticity decreases with clear structural changes, such as the changes of elastic fibers (the orderly arrangement loss, and thinning, splitting, fraying and fragmentation), an increase in collagenous Figure 1 The relationship between the changes of large arterial elasticity (DC1) and the changes of fasting serum polyunsaturated fatty acid/saturated fatty acid (P/S) ratio (DP/S ratio) in overweight hypertensive patients. The changes of large arterial elasticity (DC 1 ) are significantly associated (r ¼ 0.415, P ¼ 0.011) with the changes of fasting serum P/S (DP/S ratio) in all overweight hypertensive patients after 8 weeks intervention.
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Overweight hypertensive patients S Wang et al material and in ground substance, and calcium deposition. Arterial wall properties are also influenced by functional characteristics such as the tonicity of the artery or changes in pressure (Laurent et al., 2005) . The rapidity with which fish oil improved arterial elasticity indicates an effect on the functional components that determine elasticity. There is a clinical trial that favors the mechanistic change based on endothelium-related arterial relaxation (Chin et al., 1993) , because endothelial events influence the smooth muscle layer in the artery and also, because endothelial function is rapidly modifiable by fish oil. In addition, experiment evidence indicated that removal of the vascular endothelium in animals alters large artery stiffness, suggesting that endothelial-derived substances including nitric oxide, endothelin-1 and C-type natriuretic peptide regulate arterial stiffness in vivo (Wilkinson et al., 2004) . Fish oil fatty acids modify eicosanoid metabolism, which might in turn affect arterial compliance. In this study, it would favor the mechanism based on the results about the relationship between the changes of serum P/S ratio and the changes of large arterial elasticity. Moreover, there is a clinical trial that also favors the mechanism based on the relationship between low serum EPA to arachidonic acid ratio and arterial stiffness in community-dwelling elderly (Tomio et al., 2002) . However, Engler et al. (2003) showed that DHA-fed spontaneous hypertensive rat had improved arterial elasticity which related not to the change of contractile and vasorelaxant responses of arteries, but to the reduced BP and vascular wall thicknesses.
Although clinical trials showed the relationship of arterial elasticity with inflammation in hypertension (Mahmud et al., 2005) and levels of plasma leptin in obesity (Singhal et al., 2002) , respectively, this study did not find the significant effect of fish oil on inflammatory factor (level of serum sVCAM-1) and leptin. In addition, this study did not find either the significant effect of fish oil on serum lipid profile and insulin sensitivity in overweight hypertensive patients, which may attribute to the difference in the duration and dose of the fish oil intake in this study and others.
Conclusion
Fish oil supplement certainly would improve large arterial elasticity but no effect on BP in overweight hypertensive patients. Further study is needed to confirm the benefits of fish oil supplementation on age-related increases in arterial stiffness.
